NCT00357292View on ClinicalTrials.gov

Ocular Tolerance, Safety and Ocular Pharmacokinetics After 1 Drop of T1225 0.5, 1.0, 1.5% in 48 Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Timeline

Start Date

March 31, 2002

Study Completion Date

April 30, 2002

Conditions
Eye Infections, Bacterial
Interventions
DRUG

Azithromycin (T1225)

Sponsors

Lead Sponsor

Laboratoires Thea
All Listed Sponsors
lead

Laboratoires Thea

INDUSTRY